CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2017—ThyroSeq, a joint partnership between UPMC and CBLPath, announced the results of a double-blind, multicenter international study validating the performance of ThyroSeq V3 in thyroid nodules with indeterminate cytology. The results were presented at the 87th Annual Meeting of the American Thyroid Association, Oct. 18–22, in Victoria, British Columbia, Canada.
Read More »